Figure 2.

Gilteritinib promotes PUMA induction in CRC cells. A, HCT116 cells were treated with 50 nmol/L gilteritinib at indicated time‐point. PUMA expression was analysed by Western blotting. B, HCT116 cells were treated with 50 nmol/L gilteritinib at indicated time‐point. PUMA mRNA induction by gilteritinib was analysed by real‐time reverse transcriptase (RT) PCR. C, HCT116 cells were treated with 50 nmol/L gilteritinib at indicated time‐point. The expression of indicated Bcl‐2 family members was analysed by Western blotting. D, SW480 cells were treated with 50 nmol/L gilteritinib at indicated time‐point. PUMA expression was analysed by Western blotting. E, Indicated CRC cell lines were treated with 50 nmol/L gilteritinib for 24 hours. PUMA expression was analysed by Western blotting. F, HCT116 cells were treated with 50 nmol/L quizartinib or dovitinib at indicated time‐point. PUMA expression was analysed by Western blotting. Results in (B) were expressed as means ± SD of 3 independent experiments. **P < .01; *P < .05